| Identification | Back Directory | [Name]
AVP-13358 | [CAS]
459805-03-9 | [Synonyms]
AVP-13358
2-[4-(Adamantan-1-ylcarboxamido)phenyl]-N-(2-pyridyl)-1H-benzimidazole-5-carboxamide
1H-Benzimidazole-6-carboxamide, N-2-pyridinyl-2-[4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]phenyl]-
N-2-Pyridinyl-2-[4-[(tricyclo[3.3.1.1(3,7)]dec-1-ylcarbonyl)amino]phenyl]-1H-benzimidazole-5-carboxamide | [Molecular Formula]
C30H29N5O2 | [MDL Number]
MFCD25976424 | [MOL File]
459805-03-9.mol | [Molecular Weight]
491.584 |
| Hazard Information | Back Directory | [Uses]
AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses[1]. | [IC 50]
IL-5; IL-13; IL-4 | [References]
[1] Richards ML, et al. Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4. DOI:10.1021/jm049288j |
|
|